

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-4 (canceled)

5. (original) A substantially purified nucleic acid encoding a human Borna disease virus (BDV) p16 polypeptide comprising an amino acid residue sequence selected from the group consisting of SEQ ID NO 23, SEQ ID NO 24, SEQ ID NO 25, MNSKHSYVELKGVIVPG (SEQ ID NO 34) and RLRNIGVGPLGPDIRSSGP (SEQ ID NO 35).

6. (original) The nucleic acid according to claim 5 wherein the nucleic acid consists essentially of a nucleotide sequence of SEQ ID NO 7.

7. (original) The nucleic acid according to claim 5 wherein the nucleic acid consists essentially of a nucleotide sequence of SEQ ID NO 8.

8. (original) The nucleic acid according to claim 5 wherein the nucleic acid consists essentially of a nucleotide sequence of SEQ ID NO 9.

9. (original) A substantially purified nucleic acid encoding a human Borna disease virus (BDV) p56 polypeptide comprising an amino acid residue sequence selected from the group consisting of SEQ ID NO 26, SEQ ID NO 27, GLSCNTDSTPGLIDLEIR (SEQ ID NO 36), RSKLRRRRRDTQQIEYLV (SEQ ID NO 37) and LISLCVSLPASFARRRRLGRWQE (SEQ ID NO 38).

10. (original) The nucleic acid according to claim 9 wherein the nucleic acid consists essentially of a nucleotide sequence of SEQ ID NO 11.

11. (original) The nucleic acid according to claim 9 wherein the nucleic acid consists essentially of a nucleotide sequence of SEQ ID NO 12.

12. (original) A substantially purified nucleic acid encoding a human Borna disease virus (BDV) p40 polypeptide consisting essentially of an amino acid residue sequence selected from the group consisting of SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 30, MPPKRRLVDDADAMEDQD (SEQ ID NO 39), MEDQDDLYEPPASLPKLP (SEQ ID NO 40) and ELSGEISAIMRMIGVTGLN (SEQ ID NO 41).

13. (original) The nucleic acid according to claim 12 wherein the nucleic acid consists of a nucleotide sequence of SEQ ID NO 14.

14. (original) The nucleic acid according to claim 12 wherein the nucleic acid consists of a nucleotide sequence of SEQ ID NO 15.

15. (original) The nucleic acid according to claim 12 wherein the nucleic acid consists of a nucleotide sequence of SEQ ID NO 16.

16. (original) A substantially purified nucleic acid encoding a human Borna disease virus (BDV) catalytic domain polypeptide of L polymerase protein consisting essentially of an amino acid residue sequence in SEQ ID NO 31.

17. (original) The nucleic acid according to claim 16 wherein the nucleic acid consists of a nucleotide sequence of SEQ ID NO 18.

18. (original) The nucleic acid according to claim 16 wherein the nucleic acid consists of a nucleotide sequence of SEQ ID NO 19.

19. (currently amended) A vector containing a nucleic acid of claim 1 encoding a human Borna disease virus (BDV) p24 polypeptide comprising an amino acid residue sequence selected

from the group consisting of SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, MATGPSSLVDSLEDEEDP (SEQ ID NO 32) AND RIYPOLPSAPTADEWDIIP (SEQ ID NO 33).

20. (original) The vector according to claim 19 wherein the vector is an expression vector and the nucleic acid is operably linked to a promoter.

21. (currently amended) The vector according to claim 20 wherein the nucleic acid consists of a nucleotide sequence of claims 2, 3 or 4 SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5.

22. (original) A vector containing a nucleic acid of claim 5.

23. (original) The vector according to claim 22 wherein the vector is an expression vector and the nucleic acid is operably linked to a promoter.

24. (original) The vector according to claim 23 wherein the nucleic acid consists of a nucleotide sequence of claims 6, 7 or 8.

25. (original) A vector containing a nucleic acid of claim 9.

26. (original) The vector according to claim 25 wherein the vector is an expression vector and the nucleic acid is operably linked to a promoter.

27. (original) The vector according to claim 26 wherein the nucleic acid consists of a nucleotide sequence of claims 10 or 11.

28. (original) A vector containing a nucleic acid of claim 12.

29. (original) The vector according to claim 28 wherein the vector is an expression vector and the nucleic acid is operably linked to a promoter.

30. (original) The vector according to claim 29 wherein the nucleic acid consists of a nucleotide sequence of claims 13, 14 or 15.

31. (original) A vector containing a nucleic acid of claim 16.

32. (original) The vector according to claim 31 wherein the vector is an expression vector and the nucleic acid is operably linked to a promoter.

33. (original) The vector according to claim 32 wherein the nucleic acid consists of a nucleotide sequence of claims 17 or 18.

34. (original) A cell transformed with the expression vector of claims 20, 23, 26, 29 or 32.

35. (original) A substantially purified polypeptide corresponding to human Borna disease virus (BDV) p24 polypeptide comprising an amino acid residue sequence selected from the group consisting of SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, MATGPSSLVDSLEDEEDP (SEQ ID NO 32) and RIYPQLPSAPTADEWDIIP (SEQ ID NO 33).

36. (original) The polypeptide according to claim 35 wherein the polypeptide is a synthetic polypeptide.

37. (original) The polypeptide according to claim 35 wherein the polypeptide is a recombinant polypeptide.

38. (original) The polypeptide according to claim 37 wherein the recombinant polypeptide is a fusion protein.

39. (original) A substantially purified polypeptide corresponding to human Borna disease virus (BDV) p16 polypeptide consisting essentially of an amino acid residue sequence selected from the group consisting of SEQ ID NO 23, SEQ ID NO 24, SEQ ID NO 25, MNSKHSYVELKGKVIIVPG (SEQ ID NO 34) and RLRNIGVGPLGPDIRSSGP (SEQ ID NO 35).

40. (original) The polypeptide according to claim 39 wherein the polypeptide is a synthetic polypeptide.

41. (original) The polypeptide according to claim 39 wherein the polypeptide is a recombinant polypeptide.

42. (original) The polypeptide according to claim 41 wherein the recombinant polypeptide is a fusion protein.

43. (original) A substantially purified polypeptide corresponding to human Borna disease virus (BDV) p56 polypeptide consisting essentially of an amino acid residue sequence selected from the group consisting of SEQ ID NO 26, SEQ ID NO 27, GLSCNTDSTPGLIDLEIR (SEQ ID NO 36), RSKLRRRRRDTQQIEYLV (SEQ ID NO 37) and LISLCVSLPASFARRRRLGRWQE (SEQ ID NO 38).

44. (original) The polypeptide according to claim 43 wherein the polypeptide is a synthetic polypeptide.

45. (original) The polypeptide according to claim 43 wherein the polypeptide is a recombinant polypeptide.

46. (original) The polypeptide according to claim 45 wherein the recombinant polypeptide is a fusion protein.

47. (original) A substantially purified polypeptide corresponding to human Borna disease virus (BDV) p40 polypeptide comprising an amino acid residue sequence selected from the group consisting of SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 30, MPPKRRLVDDADAMEDQD (SEQ ID NO 39), MEDQDDLYEPPASLPKLP (SEQ ID NO 40) and ELSGEISAIMRMIGVTGLN (SEQ ID NO 41).

48. (original) The polypeptide according to claim 47 wherein the polypeptide is a synthetic polypeptide.

49. (original) The polypeptide according to claim 47 wherein the polypeptide is a recombinant polypeptide.

50. (original) The polypeptide according to claim 49 wherein the recombinant polypeptide is a fusion protein.

51. (original) A substantially purified polypeptide corresponding to human Borna disease virus (BDV) catalytic domain polypeptide of L polymerase protein consisting essentially of an amino acid residue sequence in SEQ ID NO 31.

52. (original) The polypeptide according to claim 51 wherein the polypeptide is a synthetic polypeptide.

53. (original) The polypeptide according to claim 51 wherein the polypeptide is a recombinant polypeptide.

54. (original) The polypeptide according to claim 53 wherein the recombinant polypeptide is a fusion protein.

55. (original) An anti-human BDV p24 polypeptide antibody comprising antibody molecules that immunoreact with human BDV and a polypeptide of claim 35.

56. (original) An anti-human BDV p16 polypeptide antibody comprising antibody molecules that immunoreact with human BDV and a polypeptide of claim 39.

57. An anti-human BDV p56 polypeptide antibody comprising antibody molecules that immunoreact with human BDV and a polypeptide of claim 43.

58. (original) An anti-human BDV p40 polypeptide antibody comprising antibody molecules that immunoreact with human BDV and a polypeptide of claim 47.

59. (original) An anti-human BDV catalytic domain polypeptide antibody comprising antibody molecules that immunoreact with human BDV and a polypeptide of claim 51.

Claims 60-97 (canceled)